Aptinyx Inc.
Clinical-stage biopharmaceutical company developing transformative therapies for central nervous system disorders through modulation of NMDA receptor function.
Notes
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurological disorders by modulating NMDA receptor function. The company's proprietary platform enables the development of small molecule NMDA receptor modulators with unique mechanisms of action.
The company's lead programs have targeted neuropathic pain and cognitive impairment, with NYX-2925 being a key drug candidate that advanced through clinical trials. Aptinyx has also explored treatments for fibromyalgia and other conditions involving NMDA receptor dysfunction.
Listed on NASDAQ under the ticker symbol APTX. The company is backed by Bain Capital Life Sciences among other investors.
Team
- Norbert Riedel, Ph.D. - President & Chief Executive Officer
- Former Corporate Vice President & Chief Scientific Officer at Baxter International
- Ashish Khanna - Chief Financial Officer
- Andrew Bhagwagar, M.D. - Chief Medical Officer
Additional Research Findings
- NASDAQ listed company (APTX)
- Focus on NMDA receptor modulation for CNS disorders
- Lead program NYX-2925 for neuropathic pain
- Headquarters in Evanston, Illinois
- Backed by Bain Capital Life Sciences
- Platform technology for developing small molecule NMDA receptor modulators
- Founded in 2015